These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 21166508)

  • 21. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX; Fong L; Small EJ
    Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer vaccines.
    Michael A; Relph K; Annels N; Pandha H
    Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
    Beer TM; Bernstein GT; Corman JM; Glode LM; Hall SJ; Poll WL; Schellhammer PF; Jones LA; Xu Y; Kylstra JW; Frohlich MW
    Clin Cancer Res; 2011 Jul; 17(13):4558-67. PubMed ID: 21558406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
    Thara E; Dorff TB; Pinski JK; Quinn DI
    Maturitas; 2011 Aug; 69(4):296-303. PubMed ID: 21621934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolving role of immunotherapy in prostate cancer.
    Gerritsen WR
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sipuleucel-T: Prototype for development of anti-tumor vaccines.
    Carballido E; Fishman M
    Curr Oncol Rep; 2011 Apr; 13(2):112-9. PubMed ID: 21243538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).
    Harzstark AL; Small EJ
    Expert Opin Biol Ther; 2007 Aug; 7(8):1275-80. PubMed ID: 17696825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy for castration-resistant prostate cancer.
    Sonpavde G; Kantoff PW
    Urol Clin North Am; 2012 Nov; 39(4):465-81. PubMed ID: 23084524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
    Small EJ; Schellhammer PF; Higano CS; Redfern CH; Nemunaitis JJ; Valone FH; Verjee SS; Jones LA; Hershberg RM
    J Clin Oncol; 2006 Jul; 24(19):3089-94. PubMed ID: 16809734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
    Cheng ML; Fong L
    Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integration of immunotherapy into the management of advanced prostate cancer.
    Kantoff P; Higano CS
    Urol Oncol; 2012; 30(5 Suppl):S41-7. PubMed ID: 23040162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
    Mulders PF; De Santis M; Powles T; Fizazi K
    Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sipuleucel-T in metastatic castration-resistant prostate cancer: profile report.
    Plosker GL
    BioDrugs; 2011 Aug; 25(4):255-6. PubMed ID: 21815700
    [No Abstract]   [Full Text] [Related]  

  • 34. Sipuleucel-T shows partial advantage in prostate cancer.
    Gould P
    Lancet Oncol; 2006 Sep; 7(9):710. PubMed ID: 16981300
    [No Abstract]   [Full Text] [Related]  

  • 35. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
    Dawson NA; Roesch EE
    Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.
    Patel PH; Kockler DR
    Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches.
    Arlen PM
    Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469
    [No Abstract]   [Full Text] [Related]  

  • 38. Prostate cancer vaccines: current status and future potential.
    Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
    BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.
    Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND
    Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.
    Hall SJ; Klotz L; Pantuck AJ; George DJ; Whitmore JB; Frohlich MW; Sims RB
    J Urol; 2011 Sep; 186(3):877-81. PubMed ID: 21788048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.